Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Thoolen

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology in Drug Development|December 8, 2022
Clinical Drug-Drug Interaction Between Vatiquinone, a 15-Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein SubstrateLucy Lee, Katsuyuki Murase, Jiyuan Ma, et al.
European Journal of Clinical Pharmacology|September 27, 2022
Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjectsKatsuyuki Murase, Lucy Lee, Jiyuan Ma, et al.
Clinical Pharmacology in Drug Development|August 12, 2024
Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of VatiquinoneLucy Lee, Martin Thoolen, Jiyuan Ma, et al.
Biopharmaceutics & Drug Disposition|September 16, 2025
Enhanced Vatiquinone Bioavailability With Fatty Meals and Optimal Dosing ScheduleLucy Lee, Katsuyuki Murase, Martin Thoolen, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 8, 2023
Absorption, distribution, metabolism and excretion of <sup>14</sup>C-vatiquinone in rats, dogs, and human subjectsJiyuan Ma, Lucy Lee, Bert Yao, et al.
Archives of Neurology|March 14, 2012
Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathyAlfredo A Sadun, Carlos Filipe Chicani, Fred N Ross-Cisneros, et al.
Clinical Pharmacology in Drug Development|December 14, 2022
First-in-Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15-Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral SclerosisLan Gao, Peter Giannousis, Martin Thoolen, et al.
Molecular Genetics and Metabolism|October 23, 2012
Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial diseaseFrancis G Blankenberg, Stephen L Kinsman, Bruce H Cohen, et al.
Bioorganic & Medicinal Chemistry Letters|May 24, 2011
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of agingWilliam D Shrader, Akiko Amagata, Adam Barnes, et al.
Molecular Genetics and Metabolism|November 26, 2011
Initial experience in the treatment of inherited mitochondrial disease with EPI-743Gregory M Enns, Stephen L Kinsman, Susan L Perlman, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology in Drug Development|December 8, 2022
Clinical Drug-Drug Interaction Between Vatiquinone, a 15-Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein SubstrateLucy Lee, Katsuyuki Murase, Jiyuan Ma, et al.
European Journal of Clinical Pharmacology|September 27, 2022
Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjectsKatsuyuki Murase, Lucy Lee, Jiyuan Ma, et al.
Clinical Pharmacology in Drug Development|August 12, 2024
Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of VatiquinoneLucy Lee, Martin Thoolen, Jiyuan Ma, et al.
Biopharmaceutics & Drug Disposition|September 16, 2025
Enhanced Vatiquinone Bioavailability With Fatty Meals and Optimal Dosing ScheduleLucy Lee, Katsuyuki Murase, Martin Thoolen, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 8, 2023
Absorption, distribution, metabolism and excretion of <sup>14</sup>C-vatiquinone in rats, dogs, and human subjectsJiyuan Ma, Lucy Lee, Bert Yao, et al.
Archives of Neurology|March 14, 2012
Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathyAlfredo A Sadun, Carlos Filipe Chicani, Fred N Ross-Cisneros, et al.
Clinical Pharmacology in Drug Development|December 14, 2022
First-in-Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15-Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral SclerosisLan Gao, Peter Giannousis, Martin Thoolen, et al.
Molecular Genetics and Metabolism|October 23, 2012
Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial diseaseFrancis G Blankenberg, Stephen L Kinsman, Bruce H Cohen, et al.
Bioorganic & Medicinal Chemistry Letters|May 24, 2011
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of agingWilliam D Shrader, Akiko Amagata, Adam Barnes, et al.
Molecular Genetics and Metabolism|November 26, 2011
Initial experience in the treatment of inherited mitochondrial disease with EPI-743Gregory M Enns, Stephen L Kinsman, Susan L Perlman, et al.
Pageof 2